ZURA logo

ZURA BIO LTD

ZURANASDAQ
πŸ† #2943 by market capUS Equity
$935.87β–² $71.78 (+7.67%)
Simulated price
πŸ””
Track ZURA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.7%
7dβ–² 20651.0%
14dβ–² 18921.7%
30dβ–² 16232.8%
ytdβ–² 17794.3%
1yβ–² 31305.0%
🏦Market Cap
$526M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
60
Fair

Trading Snapshot

Day Range
$930.90 – $950.23
52-Week Range
$2.07 – $7.44
Volume
$3.15B
Avg Volume
$2.46B
Shares Outstanding
95.0M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$44M
Last Q Revenue
$10M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-0.79
Dividend Yield
β€”
Dilution (1yr)
+44.2%

Why Investors Own ZURA

  • βœ“High-growth profile β€” revenue up +40.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 29% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ZURA logo

ZURA BIO LTD

ZURA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$75Mβ–² +36.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$65Mβ–² +130.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
94.2Mβ–² +44.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$109Mβ–Ό βˆ’$67M YoY
StockOtter Β· stockotter.space

About ZURA BIO LTD

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7RΞ± inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$1,119.67
β–² +19.6% Upside
High Target$1,311.54
Low Target$894.08
Based on 34 analysts

Latest News & Updates

πŸš€
ReutersΒ·2h ago

ZURA BIO LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

πŸ›°οΈ
MarketWatchΒ·5h ago

Analysts lift ZURA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
BloombergΒ·1d ago

ZURA BIO LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.